Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company... Show more
Galectin Therapeutics Inc. operates as a clinical-stage biopharmaceutical company developing therapies for fibrotic diseases and cancer. Its lead candidate, belapectin (GR-MD-02), is a galectin-3 inhibitor designed to address inflammation and fibrosis in conditions such as Metabolic Dysfunction-Associated Steatohepatitis (MASH). The company maintains a joint venture focused on oral galectin-3 inhibitors, supporting its pipeline innovation cycle. In a competitive landscape dominated by larger players in liver disease, Galectin emphasizes targeted mechanisms that could differentiate its approach in addressing portal hypertension and advanced fibrosis. Medium-term positioning hinges on successful progression through regulatory milestones and potential expansion into additional indications.
The next earnings report, scheduled for August 13, 2026, with a conference call the following day, may offer insights into financial runway extending into 2027 and operational priorities. A positive Type-C meeting with the FDA in the second quarter of 2026 has already aligned on next steps for the belapectin program, potentially informing Phase 3 planning or accelerated pathways. Biomarker data from the NAVIGATE trial continues to support disease-modifying potential, which could influence investor sentiment if further analyses emerge. Analyst sentiment remains constructive, with the lone covering firm maintaining a Strong Buy rating and $11.00 average price target as of recent updates. Rating stability or revisions from additional firms could further shape perceptions of development momentum.
The MASH therapeutics sector is evolving amid rising prevalence of metabolic liver disease, driven by obesity and diabetes trends. Regulatory climate, including FDA guidance on endpoints for cirrhosis trials, directly impacts development timelines for companies like Galectin. Broader macroeconomic factors such as interest rates affect biotech funding costs and valuation multiples, while inflation may influence clinical trial expenses. Geopolitical stability and healthcare policy shifts could alter reimbursement landscapes for future approved therapies. Technology adoption in biomarker analysis and non-invasive diagnostics supports more efficient trial designs, potentially benefiting Galectin's data-driven approach.
The Trend Prediction Engine is an AI-powered forecasting tool that helps traders identify whether a stock, ETF, or other asset may move bullish, bearish, or sideways over the next week or month. It is designed to help users spot developing trends, evaluate possible breakouts or reversals, and explore predictions across a wide range of tradable instruments. The product includes searchable prediction categories, historical context, and alert-oriented functionality. For more details on how this tool can support analysis of GALT, visit the Trend Prediction Engine.
Looking to 2026 and beyond, Galectin’s trajectory centers on advancing belapectin through regulatory and clinical milestones in MASH cirrhosis. Market expansion opportunities in the broader fibrotic disease space could emerge if data supports additional indications. Cost structure evolution will depend on efficient trial execution and potential partnerships to extend the cash runway. Margin sustainability in a pre-commercial stage remains tied to R&D prioritization and capital allocation. Technology transitions in drug delivery and biomarker validation may enhance competitive positioning against larger biopharma entrants. Regulatory developments, particularly post-FDA alignment, and long-term analyst expectations around trial success rates will likely influence sentiment. Consensus views highlight optimism around the program’s potential, though execution risks persist in the evolving MASH landscape.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
a developer of drugs to combat various diseases
Industry Biotechnology
A.I.dvisor indicates that over the last year, GALT has been loosely correlated with BCAB. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if GALT jumps, then BCAB could also see price increases.
| Ticker / NAME | Correlation To GALT | 1D Price Change % | ||
|---|---|---|---|---|
| GALT | 100% | +4.21% | ||
| BCAB - GALT | 35% Loosely correlated | +0.15% | ||
| TAOX - GALT | 32% Poorly correlated | -1.43% | ||
| RNAC - GALT | 32% Poorly correlated | +4.91% | ||
| MGTX - GALT | 28% Poorly correlated | +1.91% | ||
| HYFT - GALT | 27% Poorly correlated | -3.03% | ||
More | ||||
GALT's Aroon Indicator triggered a bullish signal on July 23, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 196 similar instances where the Aroon Indicator showed a similar pattern. In of the 196 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 63 cases where GALT's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where GALT advanced for three days, in of 227 cases, the price rose further within the following month. The odds of a continued upward trend are .
The 10-day RSI Indicator for GALT moved out of overbought territory on July 15, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 28 similar instances where the indicator moved out of overbought territory. In of the 28 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Momentum Indicator moved below the 0 level on July 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on GALT as a result. In of 104 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for GALT turned negative on July 16, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at .
GALT moved below its 50-day moving average on July 30, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for GALT crossed bearishly below the 50-day moving average on August 03, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 10 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GALT declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
GALT broke above its upper Bollinger Band on July 14, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. GALT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (20.186). P/E Ratio (0.000) is within average values for comparable stocks, (26.010). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.625). Dividend Yield (0.000) settles around the average of (0.019) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (463.196).
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GALT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.